GlassScriptPhysician profile
Tiffany Trieu
NPI 1366883217
$5,282.65
in general payments reported to CMS, 2019-2025
19 companies · $902 in 2025
The $902 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $111 · 2022: $224 · 2023: $1,494 · 2024: $2,552 · 2025: $902.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,948.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,948.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $894.48 | 2022-2025 | Cimzia, Bimzelx |
| Amgen INC. | $850.61 | 2021-2025 | Enbrel, Otezla, Evenity |
| Abbvie INC. | $765.79 | 2021-2025 | Rinvoq, Humira |
| Janssen Biotech, INC. | $622.54 | 2023-2025 | Tremfya, Simponi Aria |
| Ani Pharmaceuticals, INC. | $440.85 | 2023-2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $424.87 | 2023-2025 | Acthar |
| Astrazeneca Pharmaceuticals LP | $306.83 | 2022-2025 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $264.76 | 2023-2025 | |
| Radius Health, INC. | $239.73 | 2024-2025 | Tymlos |
| Kiniksa Pharmaceuticals International, Plc | $187.33 | 2024 | Arcalyst |
| Merz North America, INC. | $47.36 | 2025 | |
| Aurinia Pharma U.S., INC. | $46.38 | 2024 | Lupkynis |
| Kiniksa Pharmaceuticals, LTD. | $40.67 | 2023 | Arcalyst |
| Collegium Pharmaceutical, INC. | $39.12 | 2022-2023 | Belbuca |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.81 | 2024 | Cyltezo |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $22.54 | 2023 | Strensiq |
| Lilly USA, LLC | $22.18 | 2025 | Taltz |
| Fidia Pharma USA INC. | $21.67 | 2025 | Hymovis |
| Janssen Scientific Affairs, LLC | $17.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiffany Trieu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.